Monthly Communication Report

Organization:	Innovative Medicines Canada/Médicaments novateurs Canada
Associated registration:	957857-371-129
Communication date:	2025-12-01
Posted date:	2026-01-12

Designated Public Office Holders who participated in the communication:	Peter M. Boehm, Senator Senate of Canada
List of Details Subject matter Detail Foreign Affairs, Health, Intellectual Property, International Relations, International Trade, Research and Development, Science and Technology, Taxation and Finance Free trade agreements as they relate to the biopharmaceutical industry Federal-Provincial Relations, Foreign Affairs, Health, Intellectual Property, International Relations, International Trade, National Security/Security, Research and Development, Science and Technology Policy measures to ensure security of drug supply in Canada and preserve Canada's attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations
Responsible Officer who filed this communication report:	Bettina Hamelin
As the most senior paid officer, the person named above is responsible for certifying the communication report for the corporation or organization (Registrant). This person may or may not have participated in the reported communication. The Lobbyists Registration Regulations do not require that the names of in-house lobbyists (i.e. employees of corporations or organizations) who actually participated in the communication be disclosed.